ClinicalTrials.gg
CompletedNCT00762073Updated Jun 11, 2021Results posted

Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis

A Phase 2 interventional study of budesonide and placebo in Eosinophilic Esophagitis (EoE), sponsored by Shire. Completed at 20 sites in United States. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2021-06-11.

Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
2 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 18 studies testing budesonide in Eosinophilic Esophagitis — 1 open to participants now, 2 under way, 1 of them phase 3. Budesonide · Eosinophilic Esophagitis.

Enrollment
9th of 18
82 · median 79
Started
2009
the only one that year
Phase 2
7 of 18
none open now
Registered
4th of 18
by date
Lead sponsor
5 of 18
Shire

Among the 18 studies testing budesonide in Eosinophilic Esophagitis, this one is the 9th largest by enrollment, is the only one that started in 2009, is one of 7 in phase 2, and was the 4th registered.

Eosinophilic Esophagitis

235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.

Browse Eosinophilic Esophagitis studies →

Open to participants now

1 of the 18 studies testing budesonide in Eosinophilic Esophagitis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 42 Eosinophilic Esophagitis studies recruiting now, 12 (29%) set no upper age limit and 27 (64%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.

This study: 2 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing budesonide in Eosinophilic Esophagitis, or all of them as a file.
02

Study summary

This is a randomized, placebo-controlled, parallel-arm, dose-ranging study in subjects with eosinophilic esophagitis, 2-18 years of age. Eligible subjects will be randomized into one of four treatment groups. The Treatment Period will be 12 weeks during which subjects will visit the clinic at study weeks 0 (Baseline Visit), 2, 4, 8 and 12 (Final Treatment Evaluation) for clinical symptom assessment and safety evaluation (including adverse events and vital signs). All study treatments (active drug and placebo) will be administered orally twice daily during the Treatment Period, once in the morning after breakfast and once in the evening at bedtime.

03

Conditions studied

  • Eosinophilic Esophagitis (EoE)

Keywords

  • eosinophilic esophagitis
04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects between the ages of 2-18 years, inclusive
  • History of clinical symptoms of esophageal dysfunction intermittently or continuously
  • Histologic evidence of EoE with a peak eosinophil count of greater than or equal to 20 eosinophils per HPF, from two or more levels of the esophagus, within six weeks prior to the Baseline Visit
  • At the Baseline Visit, subjects must have symptoms with a total EoE Clinical Symptom Score of greater than or equal to 3
  • Willingness and ability to continue the dietary therapy, environmental therapy, and/or medical regimens (including gastric acid suppression, if any) in effect at the Screening Visit
  • Females of must have a negative serum pregnancy test (beta human chorionic gonadotropin) prior to randomization into the study and sexually active subjects must agree to continue acceptable measures throughout the duration of the study
  • Written (parent or legal guardian) and, as appropriate, subject assent

Exclusion criteria

Exclusion Criteria:

  • Current use of immunomodulatory therapy (or anticipated use within 12 weeks following the Baseline Visit)
  • Diagnosis of inflammatory bowel disease
  • Chronic viral infection or immunodeficiency condition (current)
  • Use of swallowed topical for EoE in the 1 month prior to the required for entrance to this study or at any time between the biopsy and the Baseline Visit
  • Use of systemic (oral or parenteral) corticosteroid within 1 month prior to the biopsy required for entrance to this study or at any time between the biopsy and the Baseline Visit
  • Morning plasma cortisol level below the lower limit of normal (per Central Laboratory reference range) at the Screening Visit
  • Upper gastrointestinal bleeding within 1 month prior to the Screening Visit or between the Screening Visit and Baseline Visit
  • Current use of anticoagulants
  • Current disease of the gastrointestinal tract aside from the current EoE diagnosis
  • Evidence of concurrent eosinophilic gastritis, enteritis, colitis, or proctitis
  • Evidence of active infection with Helicobacter pylori
  • Evidence of unstable asthma or changes in asthma or allergic rhinitis therapy within 1 month prior to the biopsy required for entrance to this study
  • Any female who is pregnant, who is planning to become pregnant, or who is breast-feeding
  • Current evidence or history of or idiosyncratic reaction to budesonide or any other ingredients of the study medication
  • Current evidence of oropharyngeal or esophageal candidiasis
  • Receipt of an drug within 30 days prior to the biopsy required for entrance to this study
  • Any condition or abnormality that, in the opinion of the Principal Investigator, would compromise the safety of the subject or successful conduct of the study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
82 participants (actual)

Study arms

  • Placebo comparator
    1

    Drug: placebo

  • Experimental
    2

    Low Dose Group

    Drug: budesonide

  • Experimental
    3

    Medium Dose Group

    Drug: budesonide

  • Experimental
    4

    High Dose Group

    Drug: budesonide

Interventions

  • oral suspension

  • Drugplacebo

    oral suspension matching budesonide

06

What researchers measure

Primary outcomes

  1. Percent of Participants Who Responded to Therapy

    Response was defined as a ≥50% reduction from baseline in the eosinophilic esophagitis (EoE) clinical symptom score (CSS) and a reduction in peak eosinophil count to ≤6/high power field (light microscopy) from esophageal biopsies collected at the final evaluation. The EoE CSS, scored from 0 to 18 by a doctor, assessed 6 categories: 1) heartburn, 2) abdominal pain, 3) nocturnal awakening with symptoms, 4) nausea, regurgitation, or vomiting, 5) anorexia or early satiety, and 6) dysphagia, odynophagia, or food impaction (a severe symptom). Each domain was scored as follows, based on symptoms in the 2 weeks prior to the assessment: 0 = No symptoms and no coping behaviors required; 1 = Mild: Symptoms limited to 1-3 days or no symptoms because coping behaviors were required to avoid symptoms; 2 = Moderate: Symptoms on \>3 days, with or without minor coping behaviors; 3 = Severe: Symptoms interfered with activities of daily living or symptoms persisted and required major coping behaviors.

    Time frame: 12 weeks after the start of treatment

Secondary outcomes

  1. Percent of Participants With Histologic Response

    Histologic response was defined as a maximum peak eosinophil count at the final treatment evaluation of ≤6 eosinophils/high power field (light microscopy). The maximum peak was identified by examining the peak eosinophil counts obtained from the proximal, mid, and distal esophageal biopsies and selecting the maximum value.

    Time frame: 12 weeks after the start of treatment

  2. Percent of Participants With Histologic Remission

    Histologic remission was defined as a maximum peak eosinophil count at the final treatment evaluation of ≤1 eosinophils/high power field (light microscopy). The maximum peak was identified by examining the peak eosinophil counts obtained from the proximal, mid, and distal esophageal biopsies and selecting the maximum value.

    Time frame: 12 weeks after the start of treatment

  3. Percent Change From Baseline in Peak Eosinophil Count

    The maximum peak number of eosinophils at baseline and at the final treatment evaluation was identified by examining the peak eosinophil counts obtained from the proximal, mid, and distal esophageal biopsies and selecting the maximum value. A negative change from baseline indicates that eosinophil count has decreased.

    Time frame: Baseline, 12 weeks after the start of treatment

  4. Change From Baseline in Endoscopy Score

    Esophageal endoscopy was used to assess the level of inflammation and eosinophilia. Four categories of endoscopic findings were evaluated and scored for this study: (1) pallor and diminished vascular markings; (2) furrowing with thickened mucosa; (3) presence of white mucosal plaques; and (4) concentric rings or strictures. For each category, 0 points were allocated if no esophageal sites were involved, 1 point if 1 or 2 esophageal sites were involved, and 2 points for pan-esophageal involvement (see Aceves et al., 2007). The maximum possible endoscopy score was 8 points. A negative change from baseline indicates that esophageal inflammation decreased.

    Time frame: Baseline, 12 weeks after the start of treatment

  5. Percent of Participants With Clinical Response

    Response was defined as a ≥50% reduction from baseline in the eosinophilic esophagitis (EoE) clinical symptom score (CSS). The EoE CSS, scored from 0 to 18 by a doctor, assessed 6 categories: 1) heartburn, 2) abdominal pain, 3) nocturnal awakening with symptoms, 4) nausea, regurgitation, or vomiting, 5) anorexia or early satiety, and 6) dysphagia, odynophagia, or food impaction (a severe symptom). Each domain was scored as follows, based on symptoms in the 2 weeks prior to the assessment: 0 = No symptoms and no coping behaviors required; 1 = Mild: Symptoms limited to 1-3 days or no symptoms because coping behaviors were required to avoid symptoms; 2 = Moderate: Symptoms on \>3 days, with or without minor coping behaviors; 3 = Severe: Symptoms interfered with activities of daily living or symptoms persisted and required major coping behaviors.

    Time frame: 12 weeks after the start of treatment

  6. Percent of Participants With Clinical Remission

    Clinical remission was defined as an eosinophilic esophagitis (EoE) clinical symptom score (CSS) of zero. EoE CSS, scored from 0 to 18 by a doctor, assessed 6 categories: 1) heartburn, 2) abdominal pain, 3) nocturnal awakening with symptoms, 4) nausea, regurgitation, or vomiting, 5) anorexia or early satiety, and 6) dysphagia, odynophagia, or food impaction (a severe symptom). Each domain was scored as follows, based on symptoms in the 2 weeks prior to the assessment: 0 = No symptoms and no coping behaviors required; 1 = Mild: Symptoms limited to 1-3 days or no symptoms because coping behaviors were required to avoid symptoms; 2 = Moderate: Symptoms on \>3 days, with or without minor coping behaviors; 3 = Severe: Symptoms interfered with activities of daily living or symptoms persisted and required major coping behaviors.

    Time frame: 12 weeks after the start of treatment

  7. Percent Change From Baseline in Eosinophilic Esophagitis (EoE) Clinical Symptom Score (CSS)

    The EoE CSS, scored from 0 to 18 by a doctor, assessed 6 categories: 1) heartburn, 2) abdominal pain, 3) nocturnal awakening with symptoms, 4) nausea, regurgitation, or vomiting, 5) anorexia or early satiety, and 6) dysphagia, odynophagia, or food impaction (a severe symptom). Each domain was scored as follows, based on symptoms in the 2 weeks prior to the assessment: 0 = No symptoms and no coping behaviors required; 1= Mild: Symptoms limited to 1-3 days or no symptoms because coping behaviors were required to avoid symptoms; 2= Moderate: Symptoms on \>3 days, with or without minor coping behaviors; 3= Severe: Symptoms interfered with activities of daily living or symptoms persisted and required major coping behaviors. A negative change from baseline indicates that symptoms decreased.

    Time frame: Baseline, 12 weeks after the start of treatment

  8. Change From Baseline in Physician's Global Assessment Score of Disease Severity

    Physician investigators were asked to complete a visual analog scale (VAS) to provide a global assessment of eosinophilic esophagitis (EoE) activity in each participant. The VAS was a 100-mm horizontal line on which the right extreme (100) was labeled "worst possible disease activity" and the left (0) was labeled "no disease activity." Investigators were instructed to consider the line for the VAS as a continuum with their own opinion of extremes on either end. Investigators drew a vertical line at a point that best approximated the participant's current level of EoE disease activity. The investigator was to take into consideration how esophageal disease was impacting the participant's daily activities. The following instruction was given to the investigators: "Using the visual analog scale below, please mark a vertical line on the scale to indicate your assessment of EoE activity in this participant at this time." A negative change from baseline indicates that symptoms decreased.

    Time frame: Baseline, 12 weeks after the start of treatment

  9. Maximum Plasma Concentration (Cmax) of Budesonide

    On the day that pharmacokinetic (PK) blood samples were obtained, each participant delayed the morning dose of study medication until instructed to dose in the clinic. The sampling timepoints included pre-dose (0), and 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose. The lower limit of quantitation (LLOQ) for the analytical method was approximately 20 pg/mL in plasma using 0.2 mL of the sample. Because the PK analyses for the medium and high dose oral budesonide suspension (OBS) groups were based on plasma samples collected following administration of identical single doses of OBS, the data for the medium-dose group (OBS once-daily) and high-dose group (OBS twice-daily) were summarized together.

    Time frame: Week 2, 4, or 8, or at the Final Treatment Evaluation

  10. Time to Maximum (Tmax) And Half Maximum (T1/2) Plasma Concentration of Budesonide

    On the day that pharmacokinetic (PK) blood samples were obtained, each participant delayed the morning dose of study medication until instructed to dose in the clinic. The sampling timepoints included pre-dose (0), and 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose. The lower limit of quantitation (LLOQ) for the analytical method was approximately 20 pg/mL in plasma using 0.2 mL of the sample. Because the PK analyses for the medium and high dose oral budesonide suspension (OBS) groups were based on plasma samples collected following administration of identical single doses of OBS, the data for the medium-dose group (OBS once-daily) and high-dose group (OBS twice-daily) were summarized together. T1/2 is the time to terminal elimination half-life.

    Time frame: Week 2, 4, or 8, or at the Final Treatment Evaluation

  11. Area Under The Plasma Concentration-Time Curve (AUC) of Budesonide From Time Zero to Time of The Last Measurable Concentration (AUC0-last)

    On the day that pharmacokinetic (PK) blood samples were obtained, each participant delayed the morning dose of study medication until instructed to dose in the clinic. The sampling timepoints included pre-dose (0), and 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose. The lower limit of quantitation (LLOQ) for the analytical method was approximately 20 pg/mL in plasma using 0.2 mL of the sample. Because the PK analyses for the medium and high dose oral budesonide suspension (OBS) groups were based on plasma samples collected following administration of identical single doses of OBS, the data for the medium-dose group (OBS once-daily) and high-dose group (OBS twice-daily) were summarized together.

    Time frame: Week 2, 4, or 8, or at the Final Treatment Evaluation

  12. Percent of Participants With Potential Corticosteroid-Related Treatment-Emergent Adverse Events (TEAEs)

    Corticosteroid-Related TEAEs included candidiasis, oesophageal candidiasis, crying, psychomotor hyperactivity, aggression, anger, anxiety, conduct disorder, emotional disorder, insomnia, or mood altered mood. Corticosteroid-Related TEAEs were assessed systematically during the treatment and taper periods.

    Time frame: 15 weeks after the start of treatment

  13. Mean Change in Blood Pressure (BP) at End of Treatment

    BP was assessed for each treatment group at baseline and at each post-baseline visit including the final treatment evaluation.

    Time frame: Baseline, 12 weeks after the start of treatment

07

Results

Posted Oct 5, 2015

Participant flow

Participant flow — Overall Study
MilestonePlaceboLow DoseMedium DoseHigh Dose
Started21212020
Completed17171817
Not completed4423
Withdrew: Lack of efficacy1100
Withdrew: Adverse event1011
Withdrew: Significant subject noncompliance0101
Withdrew: Withdrawal by subject1211
Withdrew: Not on treatment for >/= 77 days1000

Outcome measures

PrimaryPercent of Participants Who Responded to Therapy

Response was defined as a ≥50% reduction from baseline in the eosinophilic esophagitis (EoE) clinical symptom score (CSS) and a reduction in peak eosinophil count to ≤6/high power field (light microscopy) from esophageal biopsies collected at the final evaluation. The EoE CSS, scored from 0 to 18 by a doctor, assessed 6 categories: 1) heartburn, 2) abdominal pain, 3) nocturnal awakening with symptoms, 4) nausea, regurgitation, or vomiting, 5) anorexia or early satiety, and 6) dysphagia, odynophagia, or food impaction (a severe symptom). Each domain was scored as follows, based on symptoms in the 2 weeks prior to the assessment: 0 = No symptoms and no coping behaviors required; 1 = Mild: Symptoms limited to 1-3 days or no symptoms because coping behaviors were required to avoid symptoms; 2 = Moderate: Symptoms on \>3 days, with or without minor coping behaviors; 3 = Severe: Symptoms interfered with activities of daily living or symptoms persisted and required major coping behaviors.

Time frame:
12 weeks after the start of treatment
Reported as:
Number · percentage of participants
Percent of Participants Who Responded to Therapy
percentage of participantsPlaceboLow DoseMedium DoseHigh Dose
Percent of Participants Who Responded to Therapy5.611.852.647.1
Statistical analysis
  • Placebo vs Low Dose · Regression, Logistic · p = 0.5282 (p-values comparing each active treatment group to placebo were determined by a logistic regression analysis with treatment (all four groups) and age as main effects.) · Odds ratio (or): 2.239
  • Placebo vs Medium Dose · Regression, Logistic · p = 0.0092 (p-values comparing each active treatment group to placebo were determined by a logistic regression analysis with treatment (all four groups) and age as main effects.) · Odds ratio (or): 18.860
  • Placebo vs High Dose · Regression, Logistic · p = 0.0174 (p-values comparing each active treatment group to placebo were determined by a logistic regression analysis with treatment (all four groups) and age as main effects.) · Odds ratio (or): 15.009
SecondaryPercent of Participants With Histologic Response

Histologic response was defined as a maximum peak eosinophil count at the final treatment evaluation of ≤6 eosinophils/high power field (light microscopy). The maximum peak was identified by examining the peak eosinophil counts obtained from the proximal, mid, and distal esophageal biopsies and selecting the maximum value.

Time frame:
12 weeks after the start of treatment
Reported as:
Number · percentage of participants
Percent of Participants With Histologic Response
percentage of participantsPlaceboLow DoseMedium DoseHigh Dose
Percent of Participants With Histologic Response5.623.552.694.1
Statistical analysis
  • Placebo vs Low Dose · Regression, Logistic · p = 0.1786 (p-values were determined by a logistic regression analysis with treatment (all four groups) and age group as main effects.)
  • Placebo vs Medium Dose · Regression, Logistic · p = 0.0090 (p-values were determined by a logistic regression analysis with treatment (all four groups) and age group as main effects.)
  • Placebo vs High Dose · Regression, Logistic · p = 0.0001 (p-values were determined by a logistic regression analysis with treatment (all four groups) and age group as main effects.)
SecondaryPercent of Participants With Histologic Remission

Histologic remission was defined as a maximum peak eosinophil count at the final treatment evaluation of ≤1 eosinophils/high power field (light microscopy). The maximum peak was identified by examining the peak eosinophil counts obtained from the proximal, mid, and distal esophageal biopsies and selecting the maximum value.

Time frame:
12 weeks after the start of treatment
Reported as:
Number · percentage of participants
Percent of Participants With Histologic Remission
percentage of participantsPlaceboLow DoseMedium DoseHigh Dose
Percent of Participants With Histologic Remission0.011.842.176.5
Statistical analysis
  • Placebo vs Low Dose · Regression, Logistic · p = 0.4959 (p-values were determined by a logistic regression analysis with treatment (all four groups) and age group as main effects.)
  • Placebo vs Medium Dose · Regression, Logistic · p = 0.0040 (p-values were determined by a logistic regression analysis with treatment (all four groups) and age group as main effects.)
  • Placebo vs High Dose · Regression, Logistic · p = <0.0001 (p-values were determined by a logistic regression analysis with treatment (all four groups) and age group as main effects.)
SecondaryPercent Change From Baseline in Peak Eosinophil Count

The maximum peak number of eosinophils at baseline and at the final treatment evaluation was identified by examining the peak eosinophil counts obtained from the proximal, mid, and distal esophageal biopsies and selecting the maximum value. A negative change from baseline indicates that eosinophil count has decreased.

Time frame:
Baseline, 12 weeks after the start of treatment
Reported as:
Mean · percent change
Percent Change From Baseline in Peak Eosinophil Count
percent changePlaceboLow DoseMedium DoseHigh Dose
Percent Change From Baseline in Peak Eosinophil Count7.93 ± 84.162-52.62 ± 51.22-44.02 ± 89.106-94.75 ± 19.615
Statistical analysis
  • Placebo vs Low Dose · ANCOVA · p = 0.0108 (p-values comparing percent change from baseline for each active treatment group to placebo were determined by an ANCOVA model with treatment and age strata as main effects and baseline as a covariate.)
  • Placebo vs Medium Dose · ANCOVA · p = 0.0208 (p-values comparing percent change from baseline for each active treatment group to placebo were determined by an ANCOVA model with treatment and age strata as main effects and baseline as a covariate.)
  • Placebo vs High Dose · ANCOVA · p = <0.0001 (p-values comparing percent change from baseline for each active treatment group to placebo were determined by an ANCOVA model with treatment and age strata as main effects and baseline as a covariate.)
SecondaryChange From Baseline in Endoscopy Score

Esophageal endoscopy was used to assess the level of inflammation and eosinophilia. Four categories of endoscopic findings were evaluated and scored for this study: (1) pallor and diminished vascular markings; (2) furrowing with thickened mucosa; (3) presence of white mucosal plaques; and (4) concentric rings or strictures. For each category, 0 points were allocated if no esophageal sites were involved, 1 point if 1 or 2 esophageal sites were involved, and 2 points for pan-esophageal involvement (see Aceves et al., 2007). The maximum possible endoscopy score was 8 points. A negative change from baseline indicates that esophageal inflammation decreased.

Time frame:
Baseline, 12 weeks after the start of treatment
Reported as:
Mean · scores on a scale
Change From Baseline in Endoscopy Score
scores on a scalePlaceboLow DoseMedium DoseHigh Dose
Change From Baseline in Endoscopy Score-0.6 ± 2.28-0.9 ± 1.90-1.3 ± 2.23-2.2 ± 1.81
Statistical analysis
  • Placebo vs Low Dose · ANCOVA · p = 0.1095 (p-values comparing each active treatment group to placebo were determined by an ANCOVA model with treatment and age strata as main effects and baseline as a covariate)
  • Placebo vs Medium Dose · ANCOVA · p = 0.0264 (p-values comparing each active treatment group to placebo were determined by an ANCOVA model with treatment and age strata as main effects and baseline as a covariate)
  • Placebo vs High Dose · ANCOVA · p = 0.0010 (p-values comparing each active treatment group to placebo were determined by an ANCOVA model with treatment and age strata as main effects and baseline as a covariate)
SecondaryPercent of Participants With Clinical Response

Response was defined as a ≥50% reduction from baseline in the eosinophilic esophagitis (EoE) clinical symptom score (CSS). The EoE CSS, scored from 0 to 18 by a doctor, assessed 6 categories: 1) heartburn, 2) abdominal pain, 3) nocturnal awakening with symptoms, 4) nausea, regurgitation, or vomiting, 5) anorexia or early satiety, and 6) dysphagia, odynophagia, or food impaction (a severe symptom). Each domain was scored as follows, based on symptoms in the 2 weeks prior to the assessment: 0 = No symptoms and no coping behaviors required; 1 = Mild: Symptoms limited to 1-3 days or no symptoms because coping behaviors were required to avoid symptoms; 2 = Moderate: Symptoms on \>3 days, with or without minor coping behaviors; 3 = Severe: Symptoms interfered with activities of daily living or symptoms persisted and required major coping behaviors.

Time frame:
12 weeks after the start of treatment
Reported as:
Number · percentage of participants
Percent of Participants With Clinical Response
percentage of participantsPlaceboLow DoseMedium DoseHigh Dose
Percent of Participants With Clinical Response77.864.778.952.9
Statistical analysis
  • Placebo vs Low Dose · Regression, Logistic · p = 0.3769 (p-values comparing each active treatment group to placebo were determined by a logistic regression analysis with treatment (all four groups) and age as main effects.)
  • Placebo vs Medium Dose · Regression, Logistic · p = 0.9363 (p-values comparing each active treatment group to placebo were determined by a logistic regression analysis with treatment (all four groups) and age as main effects.)
  • Placebo vs High Dose · Regression, Logistic · p = 0.1235 (p-values comparing each active treatment group to placebo were determined by a logistic regression analysis with treatment (all four groups) and age as main effects.)
SecondaryPercent of Participants With Clinical Remission

Clinical remission was defined as an eosinophilic esophagitis (EoE) clinical symptom score (CSS) of zero. EoE CSS, scored from 0 to 18 by a doctor, assessed 6 categories: 1) heartburn, 2) abdominal pain, 3) nocturnal awakening with symptoms, 4) nausea, regurgitation, or vomiting, 5) anorexia or early satiety, and 6) dysphagia, odynophagia, or food impaction (a severe symptom). Each domain was scored as follows, based on symptoms in the 2 weeks prior to the assessment: 0 = No symptoms and no coping behaviors required; 1 = Mild: Symptoms limited to 1-3 days or no symptoms because coping behaviors were required to avoid symptoms; 2 = Moderate: Symptoms on \>3 days, with or without minor coping behaviors; 3 = Severe: Symptoms interfered with activities of daily living or symptoms persisted and required major coping behaviors.

Time frame:
12 weeks after the start of treatment
Reported as:
Number · percentage of participants
Percent of Participants With Clinical Remission
percentage of participantsPlaceboLow DoseMedium DoseHigh Dose
Percent of Participants With Clinical Remission33.317.631.617.6
Statistical analysis
  • Placebo vs Low Dose · Regression, Logistic · p = 0.3444 (p-values comparing each active treatment group to placebo were determined by a logistic regression analysis with treatment (all four groups) and age as main effects.)
  • Placebo vs Medium Dose · Regression, Logistic · p = 0.9258 (p-values comparing each active treatment group to placebo were determined by a logistic regression analysis with treatment (all four groups) and age as main effects.)
  • Placebo vs High Dose · Regression, Logistic · p = 0.3215 (p-values comparing each active treatment group to placebo were determined by a logistic regression analysis with treatment (all four groups) and age as main effects.)
SecondaryPercent Change From Baseline in Eosinophilic Esophagitis (EoE) Clinical Symptom Score (CSS)

The EoE CSS, scored from 0 to 18 by a doctor, assessed 6 categories: 1) heartburn, 2) abdominal pain, 3) nocturnal awakening with symptoms, 4) nausea, regurgitation, or vomiting, 5) anorexia or early satiety, and 6) dysphagia, odynophagia, or food impaction (a severe symptom). Each domain was scored as follows, based on symptoms in the 2 weeks prior to the assessment: 0 = No symptoms and no coping behaviors required; 1= Mild: Symptoms limited to 1-3 days or no symptoms because coping behaviors were required to avoid symptoms; 2= Moderate: Symptoms on \>3 days, with or without minor coping behaviors; 3= Severe: Symptoms interfered with activities of daily living or symptoms persisted and required major coping behaviors. A negative change from baseline indicates that symptoms decreased.

Time frame:
Baseline, 12 weeks after the start of treatment
Reported as:
Mean · percent change
Percent Change From Baseline in Eosinophilic Esophagitis (EoE) Clinical Symptom Score (CSS)
percent changePlaceboLow DoseMedium DoseHigh Dose
Percent Change From Baseline in Eosinophilic Esophagitis (EoE) Clinical Symptom Score (CSS)-64.46 ± 45.759-60.83 ± 30.347-65.89 ± 32.382-47.21 ± 40.790
Statistical analysis
  • Placebo vs Low Dose · ANCOVA · p = 0.6729 (p-values comparing percent change from Baseline for each active treatment group to placebo were determined by an ANCOVA model with treatment and age strata as main effects and baseline as a covariate.)
  • Placebo vs Medium Dose · ANCOVA · p = 0.8894 (p-values comparing percent change from Baseline for each active treatment group to placebo were determined by an ANCOVA model with treatment and age strata as main effects and baseline as a covariate.)
  • Placebo vs High Dose · ANCOVA · p = 0.1532 (p-values comparing percent change from Baseline for each active treatment group to placebo were determined by an ANCOVA model with treatment and age strata as main effects and baseline as a covariate.)
SecondaryChange From Baseline in Physician's Global Assessment Score of Disease Severity

Physician investigators were asked to complete a visual analog scale (VAS) to provide a global assessment of eosinophilic esophagitis (EoE) activity in each participant. The VAS was a 100-mm horizontal line on which the right extreme (100) was labeled "worst possible disease activity" and the left (0) was labeled "no disease activity." Investigators were instructed to consider the line for the VAS as a continuum with their own opinion of extremes on either end. Investigators drew a vertical line at a point that best approximated the participant's current level of EoE disease activity. The investigator was to take into consideration how esophageal disease was impacting the participant's daily activities. The following instruction was given to the investigators: "Using the visual analog scale below, please mark a vertical line on the scale to indicate your assessment of EoE activity in this participant at this time." A negative change from baseline indicates that symptoms decreased.

Time frame:
Baseline, 12 weeks after the start of treatment
Reported as:
Mean · scores on a scale
Change From Baseline in Physician's Global Assessment Score of Disease Severity
scores on a scalePlaceboLow DoseMedium DoseHigh Dose
Change From Baseline in Physician's Global Assessment Score of Disease Severity-38.9 ± 28.02-30.2 ± 27.11-39.3 ± 22.89-35.7 ± 28.49
Statistical analysis
  • Placebo vs Low Dose · ANCOVA · p = 0.4197 (p-values comparing each active treatment group to placebo were determined by an ANCOVA model with treatment and age strata as main effects and baseline as a covariate.)
  • Placebo vs Medium Dose · ANCOVA · p = 0.9787 (p-values comparing each active treatment group to placebo were determined by an ANCOVA model with treatment and age strata as main effects and baseline as a covariate.)
  • Placebo vs High Dose · ANCOVA · p = 0.8987 (p-values comparing each active treatment group to placebo were determined by an ANCOVA model with treatment and age strata as main effects and baseline as a covariate.)
SecondaryMaximum Plasma Concentration (Cmax) of Budesonide

On the day that pharmacokinetic (PK) blood samples were obtained, each participant delayed the morning dose of study medication until instructed to dose in the clinic. The sampling timepoints included pre-dose (0), and 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose. The lower limit of quantitation (LLOQ) for the analytical method was approximately 20 pg/mL in plasma using 0.2 mL of the sample. Because the PK analyses for the medium and high dose oral budesonide suspension (OBS) groups were based on plasma samples collected following administration of identical single doses of OBS, the data for the medium-dose group (OBS once-daily) and high-dose group (OBS twice-daily) were summarized together.

Time frame:
Week 2, 4, or 8, or at the Final Treatment Evaluation
Reported as:
Mean · pg/mL
Maximum Plasma Concentration (Cmax) of Budesonide
pg/mL0.35 mg Dose0.50 mg Dose1.4 mg Dose2.0 mg Dose
Maximum Plasma Concentration (Cmax) of Budesonide492.0 ± 417.81195.0 ± 64.371019.5 ± 670.18958.4 ± 527.64
SecondaryTime to Maximum (Tmax) And Half Maximum (T1/2) Plasma Concentration of Budesonide

On the day that pharmacokinetic (PK) blood samples were obtained, each participant delayed the morning dose of study medication until instructed to dose in the clinic. The sampling timepoints included pre-dose (0), and 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose. The lower limit of quantitation (LLOQ) for the analytical method was approximately 20 pg/mL in plasma using 0.2 mL of the sample. Because the PK analyses for the medium and high dose oral budesonide suspension (OBS) groups were based on plasma samples collected following administration of identical single doses of OBS, the data for the medium-dose group (OBS once-daily) and high-dose group (OBS twice-daily) were summarized together. T1/2 is the time to terminal elimination half-life.

Time frame:
Week 2, 4, or 8, or at the Final Treatment Evaluation
Reported as:
Mean · hours
Time to Maximum (Tmax) And Half Maximum (T1/2) Plasma Concentration of Budesonide
hours0.35 mg Dose0.50 mg Dose1.4 mg Dose2.0 mg Dose
T1/23.288 ± 0.82653.398 ± 0.78413.472 ± 2.67533.528 ± 1.0223
Tmax0.68 ± 0.3601.20 ± 0.4470.93 ± 0.3721.12 ± 0.546
SecondaryArea Under The Plasma Concentration-Time Curve (AUC) of Budesonide From Time Zero to Time of The Last Measurable Concentration (AUC0-last)

On the day that pharmacokinetic (PK) blood samples were obtained, each participant delayed the morning dose of study medication until instructed to dose in the clinic. The sampling timepoints included pre-dose (0), and 0.5, 1, 2, 3, 4, 6, and 8 hours post-dose. The lower limit of quantitation (LLOQ) for the analytical method was approximately 20 pg/mL in plasma using 0.2 mL of the sample. Because the PK analyses for the medium and high dose oral budesonide suspension (OBS) groups were based on plasma samples collected following administration of identical single doses of OBS, the data for the medium-dose group (OBS once-daily) and high-dose group (OBS twice-daily) were summarized together.

Time frame:
Week 2, 4, or 8, or at the Final Treatment Evaluation
Reported as:
Mean · hr*pg/mL
Area Under The Plasma Concentration-Time Curve (AUC) of Budesonide From Time Zero to Time of The Last Measurable Concentration (AUC0-last)
hr*pg/mL0.35 mg Dose0.50 mg Dose1.4 mg Dose2.0 mg Dose
Area Under The Plasma Concentration-Time Curve (AUC) of Budesonide From Time Zero to Time of The Last Measurable Concentration (AUC0-last)1139.5 ± 800.84743.8 ± 425.263259.3 ± 2109.373636.9 ± 1769.88
SecondaryPercent of Participants With Potential Corticosteroid-Related Treatment-Emergent Adverse Events (TEAEs)

Corticosteroid-Related TEAEs included candidiasis, oesophageal candidiasis, crying, psychomotor hyperactivity, aggression, anger, anxiety, conduct disorder, emotional disorder, insomnia, or mood altered mood. Corticosteroid-Related TEAEs were assessed systematically during the treatment and taper periods.

Time frame:
15 weeks after the start of treatment
Reported as:
Number · percentage of participants
Percent of Participants With Potential Corticosteroid-Related Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsPlaceboLow DoseMedium DoseHigh Dose
Percent of Participants With Potential Corticosteroid-Related Treatment-Emergent Adverse Events (TEAEs)9.59.521.015.0
SecondaryMean Change in Blood Pressure (BP) at End of Treatment

BP was assessed for each treatment group at baseline and at each post-baseline visit including the final treatment evaluation.

Time frame:
Baseline, 12 weeks after the start of treatment
Reported as:
Mean · mmHg
Mean Change in Blood Pressure (BP) at End of Treatment
mmHgPlaceboLow DoseMedium DoseHigh Dose
Systolic BP-1.5 ± 14.741.8 ± 11.133.5 ± 8.208.0 ± 13.58
Diastolic BP-3.1 ± 10.310.5 ± 8.893.1 ± 9.185.1 ± 8.83

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/21 (0%)10/21 (47.6%)
Low Dose—0/21 (0%)13/21 (61.9%)
Medium Dose—0/19 (0%)16/19 (84.2%)
High Dose—1/20 (5%)17/20 (85%)
Most frequent serious events
Most frequent serious events
EventPlaceboLow DoseMedium DoseHigh Dose
Diet refusalMetabolism and nutrition disorders0/210/210/191/20
Most frequent other events
Showing 10 of 61
Most frequent other events
EventPlaceboLow DoseMedium DoseHigh Dose
CoughRespiratory, thoracic and mediastinal disorders1/214/214/190/20
PyrexiaGeneral disorders3/213/212/194/20
RashSkin and subcutaneous tissue disorders0/213/213/191/20
NasopharyngitisInfections and infestations1/212/213/191/20
HeadacheNervous system disorders1/211/213/192/20
DiarrhoeaGastrointestinal disorders0/213/211/193/20
SinusitisInfections and infestations1/212/212/193/20
Nasal congestionRespiratory, thoracic and mediastinal disorders1/211/210/193/20
ConstipationGastrointestinal disorders0/211/210/193/20
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/213/212/192/20

Baseline characteristics

The Safety Analysis Set, defined as all randomized participants who received at least one dose of double-blind study drug. Treatment group assignment was the treatment actually received. One participant in the medium dose group was enrolled and randomized then withdrew consent and did not receive study drug.

Age, Continuous
Age, Continuous(years)PlaceboLow DoseMedium DoseHigh DoseTotal
Mean9.2 ± 4.369.0 ± 5.8810.2 ± 4.898.1 ± 4.589.1 ± 4.93
Age, Customized
Age, Customized(Participants)PlaceboLow DoseMedium DoseHigh DoseTotal
2 to 9 years1212101246
10 to 18 years999835
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLow DoseMedium DoseHigh DoseTotal
Female542415
Male1617171666
08

Study locations

20 sites
  • Phoenix Children's Hospital
    Phoenix, Arizona 85006, United States
  • Children's Hospital of Orange County
    Orange, California 92868, United States
  • Stanford University Medical Center
    Palo Alto, California 94305, United States
  • Rady Children's Hospital
    San Diego, California 92123, United States
  • The Children's Hospital
    Aurora, Colorado 80045, United States
  • Emory University-Emory Children's Center
    Atlanta, Georgia 30322, United States
  • Children's Center for Digestive Healthcare
    Atlanta, Georgia 30342, United States
  • Children's Memorial Hospital
    Chicago, Illinois 60614, United States
  • Center for Children's Digestive Health
    Park Ridge, Illinois 60068, United States
  • Riley Hospital for Children
    Indianapolis, Indiana 46202, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Children's Hospital Boston
    Boston, Massachusetts 02115, United States
  • The Center for Human Nutrition
    Omaha, Nebraska 68105, United States
  • Pediatric Gastroenterology and Nutrition Associates
    Las Vegas, Nevada 89109, United States
  • South Jersey Pediatric Gastroenterology
    Mays Landing, New Jersey 08330, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children's Center for Digestive Health
    Greenville, South Carolina 29615, United States
  • Children's Hospital of the King's Daughters
    Norfolk, Virginia 23507, United States
  • Virginia Commonwealth University, Medical College of Virginia
    Richmond, Virginia 23219, United States
  • Carilion Pediatric Gastroenterology
    Roanoke, Virginia 24013, United States
09

References and documents

Publications

  • Gupta SK, Hill M, Vitanza JM, Farber RH, Desai NK, Williams J, Song IH. Pharmacokinetics of Budesonide Oral Suspension in Children and Adolescents With Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr. 2022 Aug 1;75(2):186-191. doi: 10.1097/MPG.0000000000003482. Epub 2022 Jun 6. PubMed 35666852 ↗
  • Gupta SK, Vitanza JM, Collins MH. Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2015 Jan;13(1):66-76.e3. doi: 10.1016/j.cgh.2014.05.021. Epub 2014 Jun 4. PubMed 24907502 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2009 to primary completion in Apr 2010, 14 months.

Results were first posted in Oct 2015, 5 years 6 months after primary completion.

Of 24 phase 2 interventional studies under Eosinophilic Esophagitis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2008
First posted
Sep 30, 2008
StartActual
Jan 8, 2009
Primary completionActual
Apr 2, 2010
CompletionActual
Apr 2, 2010
Results first posted
Oct 5, 2015
Last update
Jun 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00762073
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Sep 30, 2008
Start date
Jan 8, 2009
Primary completion
Apr 2, 2010
Completion
Apr 2, 2010
Results posted
Oct 5, 2015
Last update
Jun 11, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion